Covid vaccines: Mixing increases reports of mild side-effects

Effects of mixing vaccines explained

Adults are more likely to report mild and moderate side-effects after mixing doses of the AstraZeneca and Pfizer Covid vaccines, a study indicates.

Chills, headaches, and muscle pain were reported more frequently when different vaccine doses were combined.

Any adverse reactions were short-lived, with no other safety concerns.

"It's a really intriguing finding and not something we were necessarily expecting," Prof Matthew Snape, from the Oxford Vaccine Group, said.

The Com-Cov study launched in February to see whether a different jab for the second dose might give longer-lasting immunity, better protection against new variants, or simply allow clinics to swap vaccines if supplies are interrupted.

The Canadian provinces of Ontario and Quebec have both said they plan to mix vaccines in the near future, amid uncertainty over shipments of the Oxford-AstraZeneca jab and concerns about rare blood clots.

The study, led by the University of Oxford, has recruited 830 volunteers aged over 50.

It is expected to publish its first full results in June.

But preliminary data has now been published in a research letter in the medical journal the Lancet.

Feverishness. Percentage reported after the second dose. Data showing the percentage of people who reported fatigue symptoms after the second dose.One in 10 volunteers given two AstraZeneca jabs four weeks apart reported feverishness - but if they received one AstraZeneca jab and one Pfizer, in any order, the proportion rose to about 34%

"The same real differences applied for other symptoms such as chills, fatigue, headache, malaise, and muscle ache," Prof Snape, the trial's chief investigator, said.

"One thing it's telling us is that you wouldn't want to vaccinate a ward full of nurses on the same day [with mixed doses of different vaccines], because you might have more absenteeism the next day."

Tags : #CovidVaccines #Com-CovStudy #OxfordVaccineGroup #AstraZeneca #Pfizer #MixingCovidVaccines

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Transforming Brain Healthcare: India's Visionary Task Force for Neurological DisordersApril 25, 2024
The Battle Against Malaria: Rising Trends and Vaccine InnovationsApril 25, 2024
Talc and Asbestos Controversy: Inside Johnson & Johnson's Courtroom StruggleApril 25, 2024
The Hidden Struggles of Parenthood: Addressing Isolation, Loneliness, and BurnoutApril 25, 2024
FDA Confirms Bird Flu Virus Remnants in Pasteurized Milk: Safety and Regulatory InsightsApril 24, 2024
Sarvodaya Hospital Redefines Total Knee Replacement Surgery with Augmented Reality April 23, 2024
Fateh Education announces partnership to expand educational opportunities for Indian studentsApril 23, 2024
10 Strategies to counter disinformation for the healthcare digital ecosystemApril 23, 2024
Is Selling Over-the-Counter (OTC) Drugs in General Stores A Step Towards Affordable Healthcare in IndiaApril 23, 2024
Student Health Crisis: Food Poisoning Incident Strikes Pune Coaching CentreApril 23, 2024
The Impact of Diabetes on Kidney Health: Diabetic Nephropathy ExplainedApril 23, 2024
Toddler Hospitalized After Consuming Expired Chocolates: Health Concerns RaisedApril 23, 2024
After months of diagnostic delay, a migrant worker could access TB services only when a community health worker met himApril 22, 2024
Indian Spices Contaminated with Cancer-Causing Chemical: Hong Kong Food Regulators Issue WarningApril 22, 2024
FTCCI organised a Workshop on Rooftop Kitchen GardeningApril 20, 2024
Children in Cities Exposed to Elevated Lead Levels: Study Reveals Urgent Health ConcernApril 20, 2024
Biocon Ventures into Weight-Loss Drug Market with Semaglutide DevelopmentApril 20, 2024
Innovative AI Assistance Empowers Moscow Doctors to Detect Cervical Spine Issues through MRI ScansApril 20, 2024
Air India Express ties up with AISATS for AeroWash Automated Aircraft Exterior Cleanings April 19, 2024
IndoSup raises strategic funding led by CCI group promoters Naresh Sharma and Satish Sharma; investors include Yatra.com’s Rohan Mittal April 19, 2024